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multicenter, prospective observational study was performed. Patients who met inclu-
sion criteria were followed-up for a period of 12 months, with 3 visits programmed 
at baseline, 6 months and 12 months. a total of 9 Spanish hospitals were involved in 
the study. Questionnaires used to measure quality of life were: EQ-5D (generic ques-
tionnaire), Minessotta living with heart failure- MLWHF (speciﬁ c questionnaire) and 
Barthel Index (index of independence). RESULTS: A total of 450 patients were 
included, 76% men, mean age was 62.6 years. 66.1% were in NYHA class II, 32.7% 
NYHA class III and 1.1% NYHA class IV. Prevalence of ischemic cardiopathy was 
33.5%. 35% of patients had an implantable device (ICD, RCT or pacemaker). Sig-
niﬁ cant differences were observed in Barthel Index’s scores depending on class: class 
I 97.6 ± 6.7 vs. Class III-IV 91.8 ± 14.6. Related to EQ-5D tariffs, individuals in class 
II had a mean value of 0.8407 ± 0.1887 (out of 1), and mean VAS value of 60.6 ± 
17.39 (out of 100). Individuals in NYHA class III or IV had a mean score of 0.6624 
± 0.2848, and mean VAS value of 51.93 ± 17.15 (out of 100). In a MLWHF question-
naire analyses, patients in NYHA class II showed a mean score of 32.52 ± 20.69 while 
patient in NYHA class III-IV showed a mean score of 50.44 ± 18.23. CONCLU-
SIONS: Our ﬁ ndings showed the results from the three questionnaires were generally 
consistent with each other and values reported from other countries in the 
literature.
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OBJECTIVES: To characterize health-related quality of life (HRQoL) in patients with 
pulmonary arterial hypertension (PAH) in relation to persons of similar age and gender 
in the general United States (US) population. METHODS: Data were obtained from 
a large phase III clinical trial in which patients (n = 274) were randomized to sildenaﬁ l 
or placebo for 12 weeks. We characterized HRQoL using responses to the Short 
Form-36 General Health Survey (SF-36) obtained at baseline; the SF-36 addresses eight 
HRQoL domains: physical functioning (PF), role functioning–physical (RP), bodily 
pain (BP), general health (GH), vitality (VT), social functioning (SF), role function-
ing–emotional (RE), and mental health (MH). Values for these eight domains were 
then standardized to US population norms for persons aged 45–54 years (mean age 
of patients in trial was 49 years). RESULTS: A total of 39% and 58% of patients 
were designated at baseline as Functional Class (FC) II and III, respectively (<1% and 
3% were designated as FC I and IV), with 75% women. Standardized mean scores 
were 30.4 for PF, 27.9 for RP, 47.8 for BP, 34.2 for GH, 41.2 for VT, 38.9 for SF, 
34.9 for RE, and 43.7 for MH. In comparison with the US population, whose mean 
score for each domain = 50, PF, RP, GH, SF, and RE were all substantially worse for 
PAH patients. Additionally MH and VT were marginally worse among PAH patients, 
and BP was comparable to US norms. CONCLUSIONS: With the exception of bodily 
pain and mental health, PAH patients have substantially poorer SF-36 scores than 
their peers in the US general population, especially in terms of physical functioning, 
role functioning-physical, role functioning-emotional, and general health.
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OBJECTIVES: The aim of the present study was to evaluate the effect of 700 mg and 
1400 mg pomegranate seed capsules on body weight and blood pressure for a period 
of 60 days at time interval 7, 14, 21, 28, 45 and 60 days respectively. METHODS: 
At the beginning of the study twenty four healthy human volunteers were selected. 
On the basis of BMI two broader groups, i.e. group 1 taking 700 mg pomegranate 
capsules and group 2 taking 1400 mg pomegranate capsules were designated and both 
the groups were subdivided on the basis of diet control and exercise i.e. group1 (IA, 
IB) and group 2(IIA, IIB). Group IA and IIA took pomegranate capsules without diet 
and exercise while IB and IIB took the capsules with diet and exercise. Hypertensive 
patients from these groups were included in both groups who were categorized and 
evaluated separately and compared with normal individuals. RESULTS: The result of 
investigation indicated that both doses of pomegranate seeds capsules had signiﬁ cantly 
reduced the body weight and blood pressure proﬁ le (both systolic and diastolic) in all 
groups when compared with their baseline values. However both doses caused equal 
reduction of body weight and blood pressure as no signiﬁ cant difference was present 
in both doses (p-value > 0.05). CONCLUSIONS: Thus on the basis of results obtained 
after conducting our study it was concluded that pomegranate seed capsules have 
established their efﬁ cacy and safety proﬁ le for obesity control and hypertension 
management.
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OBJECTIVES: To measure how VKA’s patients assess their treatment in terms of 
medication intake constraints, monitoring and psychological impact related to per-
ceived risk. METHODS: Questionnaires to patients under VKAs for at least 3 months. 
Questionnaires were distributed through 150 retail pharmacies spread over all France 
from November 2009 to March 2010. a random distribution of questionnaire was 
made. RESULTS: 1094 questionnaires were administered. Study included 58% men 
and 42% women aged >65 years for 72%; patients aged more than 75 years repre-
sented 43%. Patients were treated in majority by ﬂ uindione (82.3%) and for more 
than 3 years (65.1%). Patients were treated in majority for cardiac rhythm disorder 
(40%). More than ¾ (77%) of VKAs patients consider their treatment being a burden 
even though being vital. Treatment is judged as being a constraint because of the 
obligation to adapt dosages according to coagulation monitoring (42%), and due to 
the necessity to contact their physician after each blood sample (25%). The require-
ment to permanently have a monitoring is considered as constantly reminding the 
associated risk (65%), expectation of coagulation monitoring results generate anxiety 
for more than ¼ of patients (27%). Majority of patients acknowledge that regular 
blood sampling is a constraint (53%) and that the treatment would be more conve-
nient without these constant blood samplings (60%). In parallel, 38% of patients 
interviewed consider that the VKA treatment constraint is reinforced by the fact that 
they cannot eat what they would like. Patient preference for a new treatment is in 
priority: a treatment without regular blood sampling (62%); a treatment for which 
the daily anticoagulant dosage does not need adaptation (60%). CONCLUSIONS: 
Treatment by VKAs is perceived as burdensome and risky by a majority of patients 
due to the constant monitoring required and the uncertainty of the good blood dosage. 
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OBJECTIVES: While hypertension treatment guidelines emphasize the medical ben-
eﬁ ts of combined medication choice, consumption patterns of antihypertensive drugs 
raise worldwide several questions related to real-life therapeutic and cost-effectiveness. 
Hungary has a relatively poor track record: international comparative studies show 
Hungarian patients’ adherence to treatment to fall behind not only desirable targets 
but also international average values. In our analysis, we start from the hypothesis 
that medical beneﬁ ts achievable through combined therapy are weakened through 
inadequate patient adherence, and we investigate into the health loss caused to Hun-
garian patients by insufﬁ cient persistence in combined hypertension therapy. Our goal 
is to determine how the real-life consumption patterns of combination hypertension 
therapy impact real-life therapeutic effectiveness and cost-effectiveness. METHODS: 
We use itemized prescription-level data from the Hungarian National Health Insur-
ance Fund Administration’s (NHIFA) database. Our research covers patients whose 
therapy was initiated during 2008 or 2009 with high-value ﬁ x-dosage (one-pill) and 
non-ﬁ x-dosage (multiple-pill) angiotensin-converting enzyme inhibitor (ACEI) and 
calcium channel blocker (CCB) combinations, or angiotensin-receptor blocker (ARB) 
and CCB combinations. RESULTS: Adherence to treatment is measured as persistence 
on the initiating combination therapy. Firstly, ‘hard’ persistence (which does not allow 
for add-on therapies) and ‘add-on’ persistence (which allows for additional active 
substances being added to the therapy regime) are separately calculated, both for ﬁ x-
dosage and non-ﬁ x-dosage combinations. Secondly, if the initiating therapy is a ﬁ x-
dosage combination, parallel consumption of monocomponents is also analyzed. 
Thirdly, we carry out a switch analysis to determine the active substances that patients 
had been taking before receiving a ﬁ x-dosage combination, or take after abandoning 
the ﬁ x dosage combined therapy. CONCLUSIONS: We hypothesize that substantial 
societal loss is caused by patient non-adherence in hypertension treatment and clinical 
advantages of combination therapies are signiﬁ cantly impaired. Our research will 
deliver exact calculations for the extent of the societal loss.
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OBJECTIVES: Cardiovascular risk factors remain poorly controlled across Europe 
despite clinical guidelines. The European Study on Cardiovascular Risk Prevention 
and Management in Daily Practice (EURIKA) investigated the use of cardiovascular 
risk assessments tools and guidelines, and explored factors limiting their use. 
METHODS: Physicians (n = 806) from 12 European countries answered questions 
regarding their work setting, their assessment of patients with cardiovascular risk 
factors, and their use of risk calculation tools and clinical guidelines. RESULTS: 
Participating physicians worked in primary care centres or outpatient clinics; 63.8% 
were GPs. The majority (69.3%) reported using global risk calculation tools. Written 
charts were the preferred method (69.9%), followed by software (33.0%). The most 
popular tools were SCORE (European Society of Cardiology [ESC]; 52.4%), 
